TY - JOUR
T1 - High-performance liquid chromatographic measurement of cyclophosphamide in serum
AU - Hardy, R. W.
AU - Erlichman, C.
AU - Soldin, S. J.
PY - 1984/9
Y1 - 1984/9
N2 - The analysis of cyclophosphamide [Af, Af-bis(2-chlorethyl)-tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine-2-oxide] by high-performance liquid chromatography using ultraviolet detection is described. The method will enable measurement of serum concentrations of cyclophosphamide over a period of —24 h after a dose of 150 mg, and requires 1 ml of serum. The between-day precision of the assay at concentrations of 0.3, 1.0, and 15.0 mg/L generated coefficients of variation of 11.8, 12.2, and 7.7%, respectively. Percentages of analytical recovery of cyclophosphamide and internal standard (5-ethyl-5-p-tolylbarbituric acid) were 63 and 73%, respectively. Preliminary data providing the half-life for two patients with normal renal function are presented.
AB - The analysis of cyclophosphamide [Af, Af-bis(2-chlorethyl)-tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine-2-oxide] by high-performance liquid chromatography using ultraviolet detection is described. The method will enable measurement of serum concentrations of cyclophosphamide over a period of —24 h after a dose of 150 mg, and requires 1 ml of serum. The between-day precision of the assay at concentrations of 0.3, 1.0, and 15.0 mg/L generated coefficients of variation of 11.8, 12.2, and 7.7%, respectively. Percentages of analytical recovery of cyclophosphamide and internal standard (5-ethyl-5-p-tolylbarbituric acid) were 63 and 73%, respectively. Preliminary data providing the half-life for two patients with normal renal function are presented.
KW - Cyclophosphamide
KW - High-performance liquid chromatography
KW - Serum concentrations
UR - http://www.scopus.com/inward/record.url?scp=0021187214&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0021187214&partnerID=8YFLogxK
U2 - 10.1097/00007691-198409000-00010
DO - 10.1097/00007691-198409000-00010
M3 - Article
C2 - 6506139
AN - SCOPUS:0021187214
SN - 0163-4356
VL - 6
SP - 313
EP - 318
JO - Therapeutic Drug Monitoring
JF - Therapeutic Drug Monitoring
IS - 3
ER -